Challenges in health care delivery have compounded, with clinical staff being exposed to the Omicron COVID variant. Reduced staffing has brought on its challenges to most already-strained state health care systems and the people working in them.
However, over the past 2 years of the pandemic, technology has played an increasing role on the front end for patients and consumers at home and clinicians in the medical setting. Much more is planned in technology that will deliver efficiency, reduce risk and make available new models of care. This has the potential to touch the working lives of all stakeholders and recipients of care.
Australian Health Journal spoke leaders in health care delivery, developing or using technology to further transform healthcare.
00:50
Amanda Cattermole PSM, CEO Australian Digital Health Agency
3:44
Dr Jason King GP, Director of Clinical Services, Gurriny Yealamucka Health
7:41
Steven Flynn, General Manager, Baxter Healthcare Australia and New Zealand
11:52
Grainne O’Loughlin, CEO Karitane
Sharlene Vlahos, Director Education and Development, Karitane
16:15
Zara Lord, CEO and Founder uPaged
-
Gaining a better understanding of perimenopause and menopause
Nearly half of women seeking help for menopause symptoms are already experiencing clinically significant distress by the time they ask for support, according to a recent national benchmark report released by Metluma.
The 2026 Australian Menopause Experience Report, based on insights from 1,468 women using Metluma’s UMA40 assessment tool, found 43% triggered at least one clinical red flag at baseline (referral to a doctor within 24-48 hours), with more than one in five presenting with multiple red flags linked to more complex symptom burden.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
